OBJECTIVES: The valine (V) to leucine (L) polymorphism of the SRD5A2 gene is associated with 5-alpha reductase-2 activity; patients with the V allele have high activity and patients with the L allele have low activity. We examined whether this polymorphism predicts the presence of prostate cancer in 320 men without cancer who underwent biopsy and cancer progression in 318 men who underwent radical prostatectomy. METHODS: The effect of the SRD5A2 gene in predicting the presence of prostate cancer was examined using logistic regression analysis, controlling for established risk factors. The effect of the SRD5A2 gene in predicting prostate cancer progression was examined using a nested, matched, case-control design. Most of the participants were white. RESULTS: Of the 320 men, 158 (49.4%) were found on biopsy to have prostate cancer. The overall distribution of the V/V, V/L, and L/L genotypes was 47.5%, 42.5%, and 10.0%, respectively. The adjusted odds ratio for having prostate cancer for patients with at least one V allele was 2.53 compared with patients with the L/L genotype (P = 0.03). Of the 318 patients with cancer, 80 had biochemically detected recurrence and 238 had no evidence of recurrence. The odds ratio for progression for patients with at least one V allele was 3.32 (95% confidence interval 1.67 to 6.62, P = 0.0006) compared with patients with the L/L genotype. CONCLUSIONS: Men who have the V allele of the SRD5A2 gene have a twofold increase in the risk of prostate cancer development and an additional twofold increase in the risk of progression compared with men with the L/L genotype.
OBJECTIVES: The valine (V) to leucine (L) polymorphism of the SRD5A2 gene is associated with 5-alpha reductase-2 activity; patients with the V allele have high activity and patients with the L allele have low activity. We examined whether this polymorphism predicts the presence of prostate cancer in 320 men without cancer who underwent biopsy and cancer progression in 318 men who underwent radical prostatectomy. METHODS: The effect of the SRD5A2 gene in predicting the presence of prostate cancer was examined using logistic regression analysis, controlling for established risk factors. The effect of the SRD5A2 gene in predicting prostate cancer progression was examined using a nested, matched, case-control design. Most of the participants were white. RESULTS: Of the 320 men, 158 (49.4%) were found on biopsy to have prostate cancer. The overall distribution of the V/V, V/L, and L/L genotypes was 47.5%, 42.5%, and 10.0%, respectively. The adjusted odds ratio for having prostate cancer for patients with at least one V allele was 2.53 compared with patients with the L/L genotype (P = 0.03). Of the 318 patients with cancer, 80 had biochemically detected recurrence and 238 had no evidence of recurrence. The odds ratio for progression for patients with at least one V allele was 3.32 (95% confidence interval 1.67 to 6.62, P = 0.0006) compared with patients with the L/L genotype. CONCLUSIONS:Men who have the V allele of the SRD5A2 gene have a twofold increase in the risk of prostate cancer development and an additional twofold increase in the risk of progression compared with men with the L/L genotype.
Authors: Jonathan Beesley; Susan J Jordan; Amanda B Spurdle; Honglin Song; Susan J Ramus; Suzanne Kruger Kjaer; Estrid Hogdall; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Simon A Gayther; Paul D P Pharoah; Penelope M Webb; Georgia Chenevix-Trench Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-12 Impact factor: 4.254
Authors: D Vesprini; R K Nam; J Trachtenberg; M A Jewett; S V Tavtigian; M Emami; M Ho; A Toi; S A Narod Journal: Am J Hum Genet Date: 2001-03-14 Impact factor: 11.025
Authors: Aruna V Sarma; Rodney L Dunn; Leslie A Lange; Anna Ray; Yunfei Wang; Ethan M Lange; Kathleen A Cooney Journal: Prostate Date: 2008-02-15 Impact factor: 4.104
Authors: Charnita M Zeigler-Johnson; Elaine Spangler; Mohamed Jalloh; Serigne M Gueye; Hanna Rennert; Timothy R Rebbeck Journal: Can J Urol Date: 2008-02 Impact factor: 1.344
Authors: Tristan M Sissung; Douglas K Price; Marzia Del Re; Ariel M Ley; Elisa Giovannetti; William D Figg; Romano Danesi Journal: Biochim Biophys Acta Date: 2014-09-06